Erratum to: Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue (Breast Cancer Res Treat, (2013) 142, (283-296), 10.1007/s10549-013-2722-8);Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue

Breast Cancer Research and Treatment

Volumn 142, Issue 2, 2013, Pages 283-296

  Vilasco, Myriam ^a   Communal, Laudine ^a   Hugon Rodin, Justine ^a,c   Penault Llorca, Frédérique ^b   Mourra, Najat ^a   Wu, Zherui ^a   Forgez, Patricia ^a   Gompel, Anne ^a,c  

^a HÔPITAL SAINT ANTOINE   (France)

^b CENTRE JEAN PERRIN   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Dexamethasone; GR P Ser211; MCF 7 cells; MDA MB 231 cells; Triple negative breast cancer

Indexed keywords

BRCA1 PROTEIN; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; SMALL INTERFERING RNA;

ADULT; APOPTOSIS; ARTICLE; BREAST; CANCER CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MUTANT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADULT; APOPTOSIS; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DEXAMETHASONE; FEMALE; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HETEROZYGOTE; HUMANS; MAMMARY GLANDS, HUMAN; MIDDLE AGED; MUTATION; PHOSPHORYLATION; RECEPTORS, GLUCOCORTICOID; REFERENCE VALUES; SERINE;

EID: 84890430376     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-016-3712-4     Document Type: Erratum

References (47)

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117-1130
2. Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56:265-271
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874
4. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423
5. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ et al (2001) Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 20:77-87
6. Ma Y, Katiyar P, Jones LP, Fan S, Zhang Y, Furth PA, Rosen EM (2006) The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol 20:14-34
7. Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, Stallcup MR, Press MF, Coetzee GA (2000) Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res 60:5946-5949
8. Gorski JJ, Kennedy RD, Hosey AM, Harkin DP (2009) The complex relationship between BRCA1 and ERalpha in hereditary breast cancer. Clin Cancer Res 15:1514-1518
9. Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, Kirk JA, Clarke CL (2004) Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosomes Cancer 39:236-248
10. Bramley M, Clarke RB, Howell A, Evans DG, Armer T, Baildam AD, Anderson E (2006) Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. Br J Cancer 94:1021-1028
11. Ritter HD, Antonova L, Mueller CR (2012) The unliganded glucocorticoid receptor positively regulates the tumor suppressor gene BRCA1 through GABP beta. Mol Cancer Res 10:558-569
12. Antonova L, Mueller CR (2008) Hydrocortisone down-regulates the tumor suppressor gene BRCA1 in mammary cells: a possible molecular link between stress and breast cancer. Genes Chromosomes Cancer 47:341-352
13. Vilasco M, Communal L, Mourra N, Courtin A, Forgez P, Gompel A (2011) Glucocorticoid receptor and breast cancer. Breast Cancer Res Treat 130:1-10
14. Pan D, Kocherginsky M, Conzen SD (2011) Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res 71:6360-6370
15. Courtin A, Communal L, Vilasco M, Cimino D, Mourra N, de Bortoli M, Taverna D, Faussat AM, Chaouat M, Forgez P et al (2011) Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat 131(1):49-63
16. Wu W, Pew T, Zou M, Pang D, Conzen SD (2005) Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 280:4117-4124
17. Moran TJ, Gray S, Mikosz CA, Conzen SD (2000) The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res 60:867-872
18. Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD (2006) Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther 5:933-940
19. Burnstein KL, Bellingham DL, Jewell CM, Powell-Oliver FE, Cidlowski JA (1991) Autoregulation of glucocorticoid receptor gene expression. Steroids 56:52-58
20. Govindan MV, Pothier F, Leclerc S, Palaniswami R, Xie B (1991) Human glucocorticoid receptor gene promotor-homologous down regulation. J Steroid Biochem Mol Biol 40:317-323
21. Galliher-Beckley AJ, Cidlowski JA (2009) Emerging roles of glucocorticoid receptor phosphorylation in modulating glucocorticoid hormone action in health and disease. IUBMB Life 61:979-986
22. Vandevyver S, Dejager L, Libert C (2012) On the trail of the glucocorticoid receptor: into the nucleus and back. Traffic 13:364-374
23. Miller AL, Webb MS, Copik AJ, Wang Y, Johnson BH, Kumar R, Thompson EB (2005) p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol Endocrinol 19:1569-1583
24. Chen W, Dang T, Blind RD, Wang Z, Cavasotto CN, Hittelman AB, Rogatsky I, Logan SK, Garabedian MJ (2008) Glucocorticoid receptor phosphorylation differentially affects target gene expression. Mol Endocrinol 22:1754-1766
25. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168
26. Malet C, Gompel A, Yaneva H, Cren H, Fidji N, Mowszowicz I, Kuttenn F, Mauvais-Jarvis P (1991) Estradiol and progesterone receptors in cultured normal human breast epithelial cells and fibroblasts: immunocytochemical studies. J Clin Endocrinol Metab 73:8-17
27. Wan Y, Nordeen SK (2002) Overlapping but distinct gene regulation profiles by glucocorticoids and progestins in human breast cancer cells. Mol Endocrinol 16:1204-1214
28. Mattern J, Buchler MW, Herr I (2007) Cell cycle arrest by glucocorticoids may protect normal tissue and solid tumors from cancer therapy. Cancer Biol Ther 6:1345-1354
29. Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD (2001) Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 276:16649-16654
30. Yudt MR, Cidlowski JA (2002) The glucocorticoid receptor: coding a diversity of proteins and responses through a single gene. Mol Endocrinol 16:1719-1726
31. Arnett-Mansfield RL, Graham JD, Hanson AR, Mote PA, Gompel A, Scurr LL, Gava N, de Fazio A, Clarke CL (2007) Focal subnuclear distribution of progesterone receptor is ligand dependent and associated with transcriptional activity. Mol Endocrinol 21:14-29
32. Yan Y, Haas JP, Kim M, Sgagias MK, Cowan KH (2002) BRCA1-induced apoptosis involves inactivation of ERK1/2 activities. J Biol Chem 277:33422-33430
33. Gilmore PM, McCabe N, Quinn JE, Kennedy RD, Gorski JJ, Andrews HN, McWilliams S, Carty M, Mullan PB, Duprex WP et al (2004) BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3. Cancer Res 64:4148-4154
34. Rennstam K, Ringberg A, Cunliffe HE, Olsson H, Landberg G, Hedenfalk I (2010) Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency. Genes Chromosomes Cancer 49:78-90
35. Reiche EM, Nunes SO, Morimoto HK (2004) Stress, depression, the immune system, and cancer. Lancet Oncol 5:617-625
36. Lillberg K, Verkasalo PK, Kaprio J, Teppo L, Helenius H, Koskenvuo M (2003) Stressful life events and risk of breast cancer in 10,808 women: a cohort study. Am J Epidemiol 157:415-423
37. Hermes GL, Delgado B, Tretiakova M, Cavigelli SA, Krausz T, Conzen SD, McClintock MK (2009) Social isolation dysregulates endocrine and behavioral stress while increasing malignant burden of spontaneous mammary tumors. Proc Natl Acad Sci USA 106:22393-22398
38. Michael YL, Carlson NE, Chlebowski RT, Aickin M, Weihs KL, Ockene JK, Bowen DJ, Ritenbaugh C (2009) Influence of stressors on breast cancer incidence in the Women's Health Initiative. Health Psychol 28:137-146
39. Kricker A, Price M, Butow P, Goumas C, Armes JE, Armstrong BK (2009) Effects of life event stress and social support on the odds of a > or =2 cm breast cancer. Cancer Causes Control 20:437-447
40. Communal L, Vilasco M, Hugon-Rodin J, Courtin A, Mourra N, Lahlou N, Dumont S, Chaouat M, Forgez P, Gompel A (2012) Ulipristal acetate does not impact human normal breast tissue. Hum Reprod 27:2785-2798
41. Fernandez-Ramires R, Sole X, De Cecco L, Llort G, Cazorla A, Bonifaci N, Garcia MJ, Caldes T, Blanco I, Gariboldi M et al (2009) Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis. Br J Cancer 101:1469-1480
42. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121:2750-2767
43. Takabe S, Mochizuki K, Goda T (2008) De-phosphorylation of GR at Ser203 in nuclei associates with GR nuclear translocation and GLUT5 gene expression in Caco-2 cells. Arch Biochem Biophys 475:1-6
44. Surjit M, Ganti KP, Mukherji A, Ye T, Hua G, Metzger D, Li M, Chambon P (2011) Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 145:224-241
45. Gorski JJ, James CR, Quinn JE, Stewart GE, Staunton KC, Buckley NE, McDyer FA, Kennedy RD, Wilson RH, Mullan PB et al (2010) BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. Breast Cancer Res Treat 122:721-731
46. Gorski JJ, Savage KI, Mulligan JM, McDade SS, Blayney JK, Ge Z, Harkin DP (2011) Profiling of the BRCA1 transcriptome through microarray and ChIP-chip analysis. Nucleic Acids Res 39:9536-9548
47. Javle M, Curtin NJ (2011) The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol 3:257-267